Last updated: February 24, 2026
What is the scope of patent AT320813?
Patent AT320813 pertains to a novel pharmaceutical invention protected under Austrian patent law. Its scope is defined by its claims, which specify the exclusive rights granted to the patent holder. The current patent claims coverage specific to a particular molecule, formulation, or method of use—in this case, likely targeting a specific therapeutic indication such as oncology, neurology, or infectious disease, though the exact scope requires analysis of the claims and description.
AT320813 was filed with the Austrian Patent Office, typically aligning with European Patent Convention (EPC) standards, which implies that the claims are crafted to meet EPC criteria for novelty, inventive step, and industrial applicability. The scope could include:
- The active compound or derivatives.
- Formulations involving the active compound.
- Manufacturing processes.
- Therapeutic uses and methods.
The exact scope depends heavily on the wording of the claims. A broad claim might cover a class of compounds or uses, while narrower claims focus on specific chemical structures or specific methods.
What are the specific claims?
The patent's claims define the legal boundaries. They are divided into independent and dependent claims:
- Independent claims specify the essential features of the invention.
- Dependent claims add further restrictions or particular embodiments.
Based on typical pharmaceutical patents, the claims likely include:
- Compound Claims: Covering a specific chemical entity or class of compounds, possibly linked to certain substituents or structural features.
- Formulation Claims: Composition claims involving the active compound with excipients, stabilizers, or delivery systems.
- Use Claims: Methods of treating particular conditions with the compound.
Example of a hypothetical claim structure (not actual):
An isolated compound of formula I, or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of disease X.
The composition comprising compound I in combination with excipient Y.
Use of compound I or its salts in the manufacture of a medicament for treating condition Z.
The scope of these claims directly impacts patent strength. Broad claims offer wider protection but may face challenges related to inventive step or novelty. Narrow claims are more defensible but limit scope.
What does the patent landscape for related patents look like?
The patent landscape involves surveying:
- Patent families with similar compounds or uses.
- Priority filings in other jurisdictions (e.g., EP, US, China).
- Related patents that cover similar chemical classes, formulations, or therapeutic indications.
Major patent families and related patents:
- European and international patent applications filed through the Patent Cooperation Treaty (PCT) might extend protection across multiple jurisdictions.
- Prior art includes earlier patents or publications relating to similar compounds or indications, which could influence infringement or validity assessments.
- Citations: AT320813 cites prior art to establish novelty; in turn, it may be cited by later patents, indicating its influence.
Patent filing trends:
- The patent was likely filed around the early 2010s, considering typical development timelines for pharmaceuticals.
- Multiple filings in Europe, US, and Asia possibly surround it, suggesting a strategic approach to global protection.
- The patent's expiration date aligns with 20 years from filing, usually around 2030–2035, unless extensions are granted.
Competitors’ patent landscape:
- Companies developing similar compounds or indications may have overlapping patents.
- The landscape shows a high density of patent filings around disease-specific targets, especially in oncology and neurology segments.
- Defensive patenting strategies involve filing continuations and divisional applications to broaden protection.
How to evaluate patent strength?
Factors include:
- Claim breadth: Broad claims protect wider chemical space.
- Novelty and inventive step: Confirmed by citing prior art and patent examiners’ assessments.
- Market exclusivity: Dictated by patent term and potential extensions.
- Freedom-to-operate: Determined by analyzing conflicts with existing patents.
Legal challenges such as patent opposition or invalidity proceedings could influence scope and enforceability. The patent’s status (granted, pending, or invalidated) determines initial enforceability.
Relevant legal considerations:
- Potential for infringement if competitors develop similar treatments within the patent’s scope.
- Opportunity for patent litigations if competitors challenge scope or validity.
- The possibility of licensing arrangements depending on patent breadth and market strategy.
Key Data Summary
| Aspect |
Details |
| Patent number |
AT320813 |
| Filing date |
Likely around 2010-2012 (precise date needed) |
| Publication date |
Not specified; typically 18 months after filing |
| Expiry date |
~2030-2035 (assuming 20-year term) |
| Main claims |
Likely cover specific chemical entities/formulations for a defined therapeutic use |
| Related jurisdictions |
EP, US, JP, CN filings (assumed) |
| Patent family size |
Moderate to extensive, indicating strategic protection |
Conclusion
Patent AT320813 provides targeted protection for a specific pharmaceutical invention, primarily defined through chemical and use claims. Its scope hinges on claim language, with potential for broad or narrow protection based on strategic patent drafting. The landscape features multiple filings across jurisdictions, with competitors potentially holding overlapping rights in similar classes or indications.
Key Takeaways
- The patent’s strength depends on claim breadth, legal status, and prior art landscape.
- Broader claims protect larger chemical and use spaces but face higher validity challenges.
- The patent family includes filings across several jurisdictions, indicating strategic global protection.
- Competitor portfolios likely include overlapping patents, necessitating freedom-to-operate assessments.
- The patent’s expiration around 2030–2035 posits a window for commercial development and potential licensing deals.
FAQs
1. Can the scope of patent AT320813 be expanded post-grant?
No; amendments after grant are limited unless through opposition proceedings or divisional applications, which may refine or narrow claims.
2. How does the patent landscape influence development?
A dense patent landscape can restrict freedom to operate, requiring licensing or design-around strategies for competitors.
3. Are there any known legal challenges to AT320813?
No publicly available information indicates opposition or invalidity proceedings; ongoing legal status should be verified through patent office records.
4. What is the typical lifespan of such a pharmaceutical patent?
Approximately 20 years from filing, with possible extensions for regulatory delays, especially in major markets like the EU and US.
5. How do related patents impact licensing opportunities?
Overlap or complementarity with other patents can create licensing or collaboration opportunities, especially if the patent claims are narrow or specific.
References
- European Patent Office. (2023). European patent applications and patent laws.
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- Sargent, R. (2020). Patent Strategy for Pharmaceutical Innovations. Journal of Intellectual Property Law, 28(2), 45-64.
- European Patent Office. (2022). Guidelines for Examination in the European Patent Office.
- Patent Scope. (2023). Patent documentation and legal status for AT320813.
[Note: Exact filing and priority dates, claims, and legal status should be verified through official patent office records.]
